Charles River Laboratories Total Liabilities 2010-2024 | CRL
Charles River Laboratories total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Charles River Laboratories total liabilities for the quarter ending September 30, 2024 were $4.217B, a 1.85% decline year-over-year.
- Charles River Laboratories total liabilities for 2023 were $4.593B, a 0.63% decline from 2022.
- Charles River Laboratories total liabilities for 2022 were $4.622B, a 3.04% increase from 2021.
- Charles River Laboratories total liabilities for 2021 were $4.485B, a 32.99% increase from 2020.
| Charles River Laboratories Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $4,593 |
| 2022 | $4,622 |
| 2021 | $4,485 |
| 2020 | $3,373 |
| 2019 | $3,055 |
| 2018 | $2,536 |
| 2017 | $1,883 |
| 2016 | $1,873 |
| 2015 | $1,331 |
| 2014 | $1,195 |
| 2013 | $989 |
| 2012 | $983 |
| 2011 | $1,031 |
| 2010 | $1,045 |
| 2009 | $830 |
| Charles River Laboratories Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2024-09-30 | $4,217 |
| 2024-06-30 | $4,221 |
| 2024-03-31 | $4,507 |
| 2023-12-31 | $4,593 |
| 2023-09-30 | $4,296 |
| 2023-06-30 | $4,515 |
| 2023-03-31 | $4,586 |
| 2022-12-31 | $4,622 |
| 2022-09-30 | $4,750 |
| 2022-06-30 | $4,876 |
| 2022-03-31 | $4,460 |
| 2021-12-31 | $4,485 |
| 2021-09-30 | $4,626 |
| 2021-06-30 | $4,397 |
| 2021-03-31 | $3,621 |
| 2020-12-31 | $3,373 |
| 2020-09-30 | $3,312 |
| 2020-06-30 | $3,484 |
| 2020-03-31 | $3,546 |
| 2019-12-31 | $3,055 |
| 2019-09-30 | $3,046 |
| 2019-06-30 | $3,167 |
| 2019-03-31 | $2,526 |
| 2018-12-31 | $2,536 |
| 2018-09-30 | $2,540 |
| 2018-06-30 | $2,681 |
| 2018-03-31 | $1,858 |
| 2017-12-31 | $1,883 |
| 2017-09-30 | $1,841 |
| 2017-06-30 | $1,807 |
| 2017-03-31 | $1,818 |
| 2016-12-31 | $1,873 |
| 2016-09-30 | $1,817 |
| 2016-06-30 | $1,927 |
| 2016-03-31 | $1,319 |
| 2015-12-31 | $1,331 |
| 2015-09-30 | $1,324 |
| 2015-06-30 | $1,180 |
| 2015-03-31 | $1,180 |
| 2014-12-31 | $1,195 |
| 2014-09-30 | $1,169 |
| 2014-06-30 | $1,188 |
| 2014-03-31 | $953 |
| 2013-12-31 | $989 |
| 2013-09-30 | $984 |
| 2013-06-30 | $971 |
| 2013-03-31 | $973 |
| 2012-12-31 | $983 |
| 2012-09-30 | $968 |
| 2012-06-30 | $981 |
| 2012-03-31 | $1,001 |
| 2011-12-31 | $1,031 |
| 2011-09-30 | $1,044 |
| 2011-06-30 | $1,115 |
| 2011-03-31 | $1,180 |
| 2010-12-31 | $1,045 |
| 2010-09-30 | $1,042 |
| 2010-06-30 | $763 |
| 2010-03-31 | $803 |
| 2009-12-31 | $830 |
| 2009-09-30 | $842 |
| 2009-06-30 | $871 |
| 2009-03-31 | $870 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.266B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $92.839B | 12.14 |
| Cencora (COR) | United States | $49.468B | 18.60 |
| DiDi Global (DIDIY) | China | $22.650B | 0.00 |
| Natera (NTRA) | United States | $22.209B | 0.00 |
| ICON (ICLR) | Ireland | $16.344B | 14.56 |
| Revvity (RVTY) | United States | $15.033B | 26.11 |
| Avantor (AVTR) | United States | $14.626B | 21.93 |
| BioMerieux (BMXMF) | France | $14.203B | 0.00 |
| Viatris (VTRS) | United States | $13.523B | 4.17 |
| CochLear (CHEOY) | Australia | $12.916B | 0.00 |
| Solventum (SOLV) | United States | $12.870B | 0.00 |
| Doximity (DOCS) | United States | $10.767B | 63.37 |
| Medpace Holdings (MEDP) | United States | $10.662B | 30.04 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.135B | 0.00 |
| HealthEquity (HQY) | United States | $9.429B | 47.30 |
| Sonic Healthcare (SKHHY) | Australia | $8.657B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.301B | 29.31 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| BrightSpring Health Services (BTSG) | United States | $4.136B | 87.96 |
| Organon (OGN) | United States | $4.079B | 4.11 |
| Sotera Health (SHC) | United States | $3.875B | 20.73 |
| Surgery Partners (SGRY) | United States | $3.273B | 37.32 |
| Concentras Parent (CON) | United States | $2.998B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.937B | 0.00 |
| Premier (PINC) | United States | $2.191B | 11.40 |
| Ardent Health Partners (ARDT) | United States | $2.098B | 0.00 |
| PACS (PACS) | United States | $2.080B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.079B | 0.00 |
| Progyny (PGNY) | United States | $1.980B | 40.09 |
| GoodRx Holdings (GDRX) | United States | $1.845B | 48.40 |
| Teladoc Health (TDOC) | United States | $1.782B | 0.00 |
| Agilon Health (AGL) | United States | $1.413B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.219B | 11.92 |
| CareDx (CDNA) | United States | $1.210B | 0.00 |
| Embecta (EMBC) | United States | $1.070B | 7.48 |
| AMN Healthcare Services Inc (AMN) | United States | $1.036B | 7.02 |
| Establishment Labs Holdings (ESTA) | $0.947B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.637B | 0.00 |
| SBC Medicals (SBC) | United States | $0.518B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.505B | 0.00 |
| DocGo (DCGO) | United States | $0.490B | 18.46 |
| QDM (QDMI) | Hong Kong, SAR China | $0.480B | 12.56 |
| Sonida Senior Living (SNDA) | United States | $0.451B | 0.00 |
| Enhabit (EHAB) | United States | $0.422B | 36.52 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.280B | 0.00 |
| MultiPlan (MPLN) | United States | $0.267B | 0.00 |
| LifeMD (LFMD) | United States | $0.248B | 0.00 |
| Nutex Health (NUTX) | United States | $0.243B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.212B | 0.00 |
| Beauty Health (SKIN) | United States | $0.205B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.184B | 0.00 |
| Biodesix (BDSX) | United States | $0.151B | 0.00 |
| So-Young (SY) | China | $0.105B | 17.83 |
| Ascend Wellness Holdings (AAWH) | United States | $0.079B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.068B | 0.00 |
| ModivCare (MODV) | United States | $0.066B | 3.57 |
| Oncology Institute (TOI) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.038B | 0.00 |
| OncoCyte (OCX) | United States | $0.034B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.025B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.024B | 0.00 |
| KindlyMD (KDLY) | United States | $0.008B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |